These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30842350)

  • 21. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of drug-eluting balloon angioplasty with self-expanding interwoven nitinol stent deployment in patients with complex femoropopliteal lesions.
    Teymen B; Akturk S; Akturk U; Tdjani M
    Vascular; 2018 Feb; 26(1):54-61. PubMed ID: 28708023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-Year Clinical Follow-Up Following Bare-Nitinol Stent Implantation for Femoropopliteal Artery Disease.
    Soga Y; Takahara M; Iida O; Suzuki K; Mori S; Kawasaki D; Haraguchi K; Yamaoka T; Ando K
    J Atheroscler Thromb; 2022 Oct; 29(10):1448-1457. PubMed ID: 34911883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
    Iida O; Yokoi H; Soga Y; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Shintani Y; Miyamoto A; Hirano K; Miyashita Y; Tsuchiya T; Shinozaki N; Nakamura M; Isshiki T; Hamasaki T; Nanto S;
    Circulation; 2013 Jun; 127(23):2307-15. PubMed ID: 23652861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral Stent Thrombosis Leading to Acute Limb Ischemia and Major Amputation: Incidence and Risk Factors in the Aortoiliac and Femoropopliteal Arteries.
    Katsanos K; Al-Lamki SA; Parthipun A; Spiliopoulos S; Patel SD; Paraskevopoulos I; Zayed H; Diamantopoulos A
    Cardiovasc Intervent Radiol; 2017 Mar; 40(3):351-359. PubMed ID: 27921154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship Between Primary Patency and Lesion Length Following Bare Nitinol Stent Placement for Femoropopliteal Disease.
    Soga Y; Takahara M; Iida O; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Yamaoka T; Ando K
    J Endovasc Ther; 2015 Dec; 22(6):862-7. PubMed ID: 26438352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First clinical experience with the Innova versus the Protege EverFlex self-expanding bare metal stents in superficial femoral artery occlusions.
    Gabrielli R; Rosati MS; Chiappa R; Millarelli M; Marcuccio L; Siani A; Caselli G
    Thorac Cardiovasc Surg; 2015 Mar; 63(2):158-63. PubMed ID: 25602844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial.
    Garcia L; Jaff MR; Metzger C; Sedillo G; Pershad A; Zidar F; Patlola R; Wilkins RG; Espinoza A; Iskander A; Khammar GS; Khatib Y; Beasley R; Makam S; Kovach R; Kamat S; Leon LR; Eaves WB; Popma JJ; Mauri L; Donohoe D; Base CC; Rosenfield K;
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25969545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Spot versus Long Stenting for Femoropopliteal Artery Disease.
    Ko YG; Ahn CM; Rha SW; Yu CW; Park SH; Lee SJ; Lee JH; Her SH; Kang WC; Cho YS; Seo JB; Cho YH; Choi D;
    Ann Vasc Surg; 2019 Jul; 58():101-107. PubMed ID: 30769056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation.
    Rocha-Singh KJ; Beckman JA; Ansel G; Lyden SP; Schneider P; Mehta M; Dake M; Mullin CM; Jaff MR;
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1250-1256. PubMed ID: 28303688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
    Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis.
    Sabeti S; Schillinger M; Amighi J; Sherif C; Mlekusch W; Ahmadi R; Minar E
    Radiology; 2004 Aug; 232(2):516-21. PubMed ID: 15286322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MISAGO 2: one-year outcomes after implantation of the Misago self-expanding nitinol stent in the superficial femoral and popliteal arteries of 744 patients.
    Schulte KL; Kralj I; Gissler HM; Bagnaschino LA; Buschmann I; Pernès JM; Haage P; Goverde P; Beregi JP; Válka M; Boudny J; Geibel T; Velkoborsky M; Zähringer M; Paetzel C; Fanelli F; Müller-Hülsbeck S; Zeller T; Langhoff R
    J Endovasc Ther; 2012 Dec; 19(6):774-84. PubMed ID: 23210876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    JACC Cardiovasc Interv; 2014 Jul; 7(7):792-8. PubMed ID: 25060024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
    J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis.
    Kawamura Y; Ishii H; Aoyama T; Tanaka M; Takahashi H; Kumada Y; Toriyama T; Murohara T
    J Vasc Surg; 2009 Nov; 50(5):1057-62. PubMed ID: 19782527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.